Director/PDMR Shareholding
Deutsche Grundstuckautionen AG
€9.05
11:04 25/04/24
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Ms E N Walmsley | ||||
b) | Position/status | Chief Executive Officer | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)       | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr R G Connor | ||||
b) | Position/status | President, Global Vaccines | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)       | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
ÂÂ
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Ms D Conrad | ||||
b) | Position/status | SVP, Human Resources | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
  | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)       | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr S P Dingemans | ||||
b) | Position/status | Executive Director | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)       | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
ÂÂ
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr J Ford | ||||
b) | Position/status | SVP & General Counsel | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 Â | ||||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)  | ||||
e) | Date of the transaction | 2019-04-12 | ||||
f) | Place of the transaction  | New York Stock Exchange (XNYS) |
Â
Â
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr J Ford | ||||
b) | Position/status | SVP & General Counsel | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)       | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
ÂÂ
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr N Hirons | ||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053Â Â | ||||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2019 | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction) Â
 | ||||
e) | Date of the transaction | 2019-04-12 | ||||
f) | Place of the transaction  | New York Stock Exchange (XNYS) |
Â
Â
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr N Hirons | ||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)      | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
ÂÂ
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr D Jackson | ||||
b) | Position/status | Â PCA of Ms S Jackson (SVP, Global Communications and CEO Office) | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)  Â
  | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
ÂÂ
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mrs S Jackson | ||||
b) | Position/status | Â SVP, Global Communications and CEO Office | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)  Â
  | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr B McNamara | ||||
b) | Position/status | CEO, GSK Consumer Healthcare | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053Â Â | ||||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2019 | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)     | ||||
e) | Date of the transaction | 2019-04-12 | ||||
f) | Place of the transaction  | New York Stock Exchange (XNYS) |
Â
Â
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr D Redfern | ||||
b) | Position/status | Chief Strategy Officer | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)       | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
Â
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr R Simard | ||||
b) | Position/status | President, Pharma Supply Chain | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)       | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
Â
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr P C Thomson | ||||
b) | Position/status | President, Global Affairs | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)  Â
  | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mrs K Thomson | ||||
b) | Position/status | Â PCA of Mr P C Thomson (President, Global Affairs) | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â Â | ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019. | ||||
c) | Price(s) and volume(s) |
   | ||||
d) | Aggregated information  Aggregated volume Price | n/a (single transaction)     | ||||
e) | Date of the transaction | 2019-04-15 | ||||
f) | Place of the transaction  | London Stock Exchange (XLON) |
Â
Â
Â
Â
Â
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.